MCF7/AnaR-2 Cell Line

MCF7/AnaR-2 is a cell culture model mimicking acquired resistance of aromatase inhibitors (AIs) – an anti-cancer therapy. This breast cancer cell line was established from MCF7/S0.5 cells, which originates from MCF7 cells. The cellular classification is epithelial, and their shape is polygonal. The MCF7/AnaR-2 cell line is resistant to the third generation AI – anastrozole […]

Contributors

Inventor Institute
Anne Lykkesfeldt Danish Cancer Society, Denmark
Cat. #: 152552
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer;Drug development
Organism: Human
Tissue: Breast
Gender: Female
Growth properties: Adherent: breast cancer cell line resistant to the aromatase inhibitor anastrozole. Estrogen receptor positive.
Cancer Types In Detail: Breast cancer
Primary citation: Hole et al. 2015. Int J Oncol. 46(4):1481-1490. PMID: 25625755.
Alternate name: MCF-7/AnaR-2; AnaR-2
Product description: MCF7/AnaR-2 is a cell culture model mimicking acquired resistance of aromatase inhibitors (AIs) – an anti-cancer therapy. This breast cancer cell line was established from MCF7/S0.5 cells, which originates from MCF7 cells. The cellular classification is epithelial, and their shape is polygonal. The MCF7/AnaR-2 cell line is resistant to the third generation AI – anastrozole (Arimidex). MCF7/AnaR-2 is oestrogen receptor positive. Third generation AIs have proven to be effective treatment for oestrogen receptor positive (ER+) breast cancer and as such are recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients. Previous applications of this cell line include western blot analysis of protein expression. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI anastrozole allows the study of the molecular basis for AI resistance to find new targets for treatment.
Gender: Female
Conditional: No
Production details: Anastrozole-resistant cell lines were established from MCF7/S0.5 cells grown in medium with 10% NCS and 10-7 M testosterone. A culture of MCF7/S0.5 cells were treated with 10-7 M anastrozole for one week, trypsinised and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with anastrozole. After 2-3 months, the isolated colonies gave rise to anastrozole-resistant cell lines, which could be grown in anastrozole-containing medium with a weekly split ratio of 1:25. This cell line was authenticated in January 2014 by DNA profiling using short tandem repeat loci and found to be matching the genetic profile reported for the MCF7 cell line.
Cellosaurus ID: CVCL_5A10
Parental cell line: MCF7/S0.5
disease: Cancer
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 0.1 uM anastrozole.
Temperature: 37° C
Atmosphere: Humidified air with 5% CO2
References:

Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

Related Tools for Cell lines

Cat. # Tool Name
151425 TR146 Cell Line Key Info View Tool
151446 FLYRD18 Cell Line Key Info View Tool
151488 B6.1.1 Mouse ES Cell Line Key Info View Tool
151626 A375P beta6-puro Cell Line Key Info View Tool
151448 CMT 167 Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.